|
||||||
Executive Summary Galderma S.A.-Product Pipeline Review-2015 Summary Global Markets Direct's, 'Galderma S.A.-Product Pipeline Review-2015', provides an overview of the Galderma S.A.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Galderma S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope The report provides brief overview of Galderma S.A. including business description, key information and facts, and its locations and subsidiaries The report reviews current pipeline of Galderma S.A.'s human therapeutic division and enlists all their major and minor projects The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones Special feature on out-licensed and partnered product portfolio The report summarizes all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Galderma S.A.'s pipeline products Reasons To Buy Evaluate Galderma S.A.'s strategic position with total access to detailed information on its product pipeline Assess the growth potential of Galderma S.A. in its therapy areas of focus Identify new drug targets and therapeutic classes in the Galderma S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps Develop strategic initiatives by understanding the focus areas of Galderma S.A. and exploit collaboration and partnership opportunities Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Plan mergers and acquisitions effectively by identifying the most promising pipeline of Galderma S.A. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Explore the dormant and discontinued projects of Galderma S.A. and identify potential opportunities in those areas Avoid Intellectual Property Rights related issues Read More Contact Us:
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Galderma S.A. Snapshot 5 Galderma S.A. Overview 5 Key Information 5 Key Facts 5 Galderma S.A.-Research and Development Overview 6 Key Therapeutic Areas 6 Galderma S.A.-Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products-Monotherapy 9 Pipeline Products-Combination Treatment Modalities 10 Pipeline Products-Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Galderma S.A.-Pipeline Products Glance 13 Galderma S.A.-Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 Galderma S.A.-Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Galderma S.A.-Early Stage Pipeline Products 16 Discovery Products/Combination Treatment Modalities 16 Galderma S.A.-Unknown Stage Pipeline Products 17 Unknown Products/Combination Treatment Modalities 17 Galderma S.A.-Drug Profiles 18 (adapalene + benzoyl peroxide) 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 trifarotene 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CD2475/101 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 resiquimod 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Galderma S.A.-Pipeline Analysis 22 Galderma S.A.-Pipeline Products by Target 22 Galderma S.A.-Pipeline Products by Route of Administration 23 Galderma S.A.-Pipeline Products by Molecule Type 24 Galderma S.A.-Pipeline Products by Mechanism of Action 25 Galderma S.A.-Recent Pipeline Updates 26 Galderma S.A.-Dormant Projects 27 Galderma S.A.-Company Statement 28 Galderma S.A.-Locations And Subsidiaries 29 Head Office 29 Other Locations & Subsidiaries 29 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 32 Disclaimer 33 List of Tables Galderma S.A., Key Information 5 Galderma S.A., Key Facts 5 Galderma S.A.-Pipeline by Indication, 2015 7 Galderma S.A.-Pipeline by Stage of Development, 2015 8 Galderma S.A.-Monotherapy Products in Pipeline, 2015 9 Galderma S.A.-Combination Treatment Modalities in Pipeline, 2015 10 Galderma S.A.-Partnered Products in Pipeline, 2015 11 Galderma S.A.-Partnered Products/ Combination Treatment Modalities, 2015 12 Galderma S.A.-Phase III, 2015 13 Galderma S.A.-Phase II, 2015 14 Galderma S.A.-Phase I, 2015 15 Galderma S.A.-Discovery, 2015 16 Galderma S.A.-Unknown, 2015 17 Galderma S.A.-Pipeline by Target, 2015 22 Galderma S.A.-Pipeline by Route of Administration, 2015 23 Galderma S.A.-Pipeline by Molecule Type, 2015 24 Galderma S.A.-Pipeline Products by Mechanism of Action, 2015 25 Galderma S.A.-Recent Pipeline Updates, 2015 26 Galderma S.A.-Dormant Developmental Projects,2015 27 Galderma S.A., Other Locations 29 Galderma S.A., Subsidiaries 30 List of Figures Galderma S.A.-Pipeline by Top 10 Indication, 2015 7 Galderma S.A.-Pipeline by Stage of Development, 2015 8 Galderma S.A.-Monotherapy Products in Pipeline, 2015 9 Galderma S.A.-Partnered Products in Pipeline, 2015 11 Galderma S.A.-Pipeline by Top 10 Target, 2015 22 Galderma S.A.-Pipeline by Top 10 Route of Administration, 2015 23 Galderma S.A.-Pipeline by Top 10 Molecule Type, 2015 24 Galderma S.A.-Pipeline Products by Top 10 Mechanism of Action, 2015 25 Single User License: Site License: Corporate User License: Current R&D Portfolio of Galderma S.A.; Galderma S.A. - Key Therapeutics; Galderma S.A. - Pipeline Overview and Promising Molecules; Galderma S.A. - News; Galderma S.A. - Latest Updates; Galderma S.A. - Pipeline; Galderma S.A. - Discontinued/Dormant Projects |
select a license |
||
NEWSLETTER BY CATEGORY
|
||
Testimonials
|
||
The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements.... "Senior Associate, Booz Allen Hamilton"This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center" |